---
figid: PMC2570700__nihms67164f1
figlink: /pmc/articles/PMC2570700/figure/F1/
number: Figure 1
caption: After EGF binds to its receptor, conformational changes induce the activity
  of the Tyrosine Kinase domain (TK). This signal is amplified through the PI3K and
  RAS pathways leading to proliferation of cancer cells and the transcription of signals
  that favor the aggressiveness, survival and invasiveness. Cetuximab and Matuzumab
  prevent the binding of EGFR to their ligands. Gefitinib and Erlotinib inhibit the
  activity of the Tyrosine Kinase Domain. When VEGF binds to its receptor it also
  induces the formation of a dimer that triggers the activity of the Tyrosine Kinase
  domain. Through the RAS pathway VEGF increases the proliferation of endothelial
  cells. Bevacizumab prevents the binding of VEGF to its receptor. Valatinib and Sorafenib
  are inhibitors of the TK domain of the VEGF receptor. Vandetanib inhibits the TK
  domain in both VEGF and EGF receptors.
pmcid: PMC2570700
papertitle: MOLECULAR TARGETED THERAPIES FOR PANCREATIC CANCER.
reftext: Daniel Borja-Cacho, et al. Am J Surg. ;196(3):430-441.
pmc_ranked_result_index: '88386'
pathway_score: 0.9822103
filename: nihms67164f1.jpg
figtitle: MOLECULAR TARGETED THERAPIES FOR PANCREATIC CANCER
year: ''
organisms: Homo sapiens
ndex: 9e876274-deb9-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2570700__nihms67164f1.html
  '@type': Dataset
  description: After EGF binds to its receptor, conformational changes induce the
    activity of the Tyrosine Kinase domain (TK). This signal is amplified through
    the PI3K and RAS pathways leading to proliferation of cancer cells and the transcription
    of signals that favor the aggressiveness, survival and invasiveness. Cetuximab
    and Matuzumab prevent the binding of EGFR to their ligands. Gefitinib and Erlotinib
    inhibit the activity of the Tyrosine Kinase Domain. When VEGF binds to its receptor
    it also induces the formation of a dimer that triggers the activity of the Tyrosine
    Kinase domain. Through the RAS pathway VEGF increases the proliferation of endothelial
    cells. Bevacizumab prevents the binding of VEGF to its receptor. Valatinib and
    Sorafenib are inhibitors of the TK domain of the VEGF receptor. Vandetanib inhibits
    the TK domain in both VEGF and EGF receptors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CHUK
  - IKBKB
  - VEGFD
  - PGF
  - IKBKG
  - VEGFB
  - VEGFC
  - VEGFA
  - MAPK1
  - MAPK3
  - AKT3
  - SOS1
  - NRAS
  - PIK3CD
  - PIK3R5
  - PIK3CB
  - SOS2
  - EGFR
  - PIK3CA
  - MAP2K2
  - NFKB1
  - AKT2
  - AKT1
  - RAF1
  - HRAS
  - KRAS
  - EGF
  - PIK3R6
  - PIK3CG
  - MAP2K1
  - PIK3R3
  - PIK3R4
  - Vandetanib
  - Cancer
  - Lung cancer
  - Noonan syndrome
genes:
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: CHUK
  entrez: '1147'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKB
  entrez: '3551'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKG
  entrez: '8517'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Raf-1
  symbol: Raf-1
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals:
- word: Vandetanib
  source: MESH
  identifier: C452423
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
